---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-26-032247"
form_type: "8-K"
ticker: "FEMY"
cik: "0001339005"
company_name: "FEMASYS INC"
filed_at: "2026-08-11T20:40:15+00:00"
generated_at: "2026-08-11T20:41:14.627600+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Femasys closes ~$30M private placement of stock, pre-funded and milestone warrants

## Summary
- Private placement: 5,013,559 shares, 4,361,440 pre-funded warrants, and 18,749,998 warrants at $3.20/share; ~$30M gross proceeds.
- Common warrants exercisable at $2.95; pre-funded at $0.0001; milestone warrants require $1.5M quarterly revenue and 130% price trigger.
- Insiders (CEO, CFO, COO, CTO, Chief Medical Officer) purchased ~$134k of securities on same terms as other investors.
- Nantahala Capital (lead investor) gets board designee rights (up to 2) subject to ownership thresholds; prior board nomination rights from Pointillist convertible note terminated.
- Registration rights agreement: file resale registration statement within 30 days of closing (August 10, 2026).

## SEC filing metadata
- accession: 0001140361-26-032247
- form_type: 8-K
- ticker: FEMY
- cik: 0001339005
- company_name: FEMASYS INC
- filed_at: 2026-08-11T20:40:15+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01, 3.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1339005/000114036126032247/0001140361-26-032247-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1339005/000114036126032247/ef20079916_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-26-032247
- JSON: https://secwatch.observer/filing/0001140361-26-032247.json
- Plain text: https://secwatch.observer/filing/0001140361-26-032247.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.